In his weekly clinical update, Dr. Griffin discusses the use of monoclonal antibody therapy to prevent RSV hospitalization of infants and use of GSK’s RSV vaccine Arexy to prevent severe disease following RSV infection in adults between 50-59 years before he reviews recent statistics on the circulation of respiratory syncytial virus, influenza virus and SARS-CoV-2 virus, including all circulating variants in the US, discusses if how the influenza vaccine is manufactured can reprogram the antibody response, cardiovascular consequences of influenza infection, mortality of chikungunya virus infection, if an alternative vaccination schedule impacts the anti-SARS-CoV-2 immune response, dispels the myth that increased mortality correlated with the first vaccine dose, continues to dispel the myth of viral rebound, how to pay for paxlovid, when to use steroids and the benefits of convalescent plasma, how manage long COVID including prevent burnout and compassion fatigue of caring for long COVID patients, whether the CDC or WHO definition of long COVID is beneficial or the use of directed questions, baselines test and listening to the patient tell their story are beneficial in making a long COVID diagnosis.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Nirsevimab immunoprophylaxis to prevent RSV hospitalization (Eurosurveillance.)
• Arexvy given Priority Review in US for the prevention of RSV disease in adults aged 50-59 (GSK)
• Respiratory  disease surveillance (CDC)
• RSV surveillance  (CDC)
• RSV national trend (CDC)
• Can antibodies be redirected from egg adapted epitopes using recombinant or cell cultured based influenza vaccines (Nat)
• Can influenza infection lead to cardiovascular events (JID)
• Risk of death after chikungunya infection and disease (Lancet)
• Influenza/flu surveillance (CDC)
• Influenza/flu map (CDC)
• COVID-19  hospital admissions (CDC)
• COVID-19 national trend (CDC)
• COVID-19 wastewater testing (biobot)
• Variant tracker (CDC) 
• Variant hospital admissions (CDC)
• Alternative intervals between vaccine doses (Nat Comm) 
• Early mortality after first vaccination dose (CID)
• CDC Quarantine guidelines (CDC)
• To rebound or to not rebound (MMWR)
• Know your COVID-19 tools (ESMED) 
• How to pay for Paxlovid (PAXCESS) 
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Steroids, dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Burnout compassion fatigue Long COVID (OFID) 
• Scoring PASC (JAMA) 
• What is your definition of the Long COVID (WHO)
• Contribute to our ASTMH fundraiser at PWB
• Letters read on TWiV 1088
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]